摘要
目的探讨阿加曲班联合尿激酶治疗急性下肢深静脉血栓(DVT)的临床应用价值。方法选择该科2009年1月至2011年12月收治的60例急性下肢DVT患者,随机分为实验组和对照组各30例,实验组患者给予阿加曲班注射液联合尿激酶治疗,对照组患者给予低分子肝素钙联合尿激酶治疗,共治疗2周。比较两组患者临床疗效的差异,并在治疗过程中监测凝血指标(PT、TT和APTT)及PLT变化。结果实验组临床疗效优于对照组(P<0.05),两组患者凝血指标(PT、TT和APTT)及PLT变化均处于正常范围。结论阿加曲班联合尿激酶治疗急性下肢DVT,疗效可靠,不良反应小,值得进一步行大规模试验。
Objective To study the effects of argatroban combined with urokinase for treatment of acute lower limb deep venous thrombosis. Methods 60 patients with lower limb deep venous thrombosis in our hospital from Jan. 2009 to Dec. 2011 were randomly divided into argatroban group and control group. The patients of argatroban group were treated with argatroban combined with urokinase and the patients of control group were treated with low molecular weight heparin calium combined with urokinase for 2 weeks. The clinical effects of the two groups were compared and PT,TT, APTT and PLT were measured during the treatment period. Results Effects of the argatroban group were significantly better than the control group（P〈0. 05）. Conclusion Argatroban combined with urokinase is a kind of safe and effective therapy for deep venous thrombosis of lower limb.
出处
《重庆医学》
CAS
CSCD
北大核心
2012年第29期3064-3065,3067,共3页
Chongqing medicine
